Twitxy
Saved
@ThomasTreibel's profile picture
View on X

Thomas Treibel

@ThomasTreibel

Cardiology Consultant & BHF Intermediate Clinical Research Fellow @UCL & @BartsHeartCentre. #MultimodalityImaging #ValvularHeartDisease #CMR
London, England Joined June 2018
324 Following 921 Followers 261 Posts

Latest posts 5

Thomas Treibel @ThomasTreibel
3/3_🧠 Implication:
Dual pathology (AS + ATTR-CA) should not preclude intervention.
Combined AVR and disease-modifying therapy may restore prognosis.
Non-randomised, but compelling signal for integrated treatment. @EurHeartJ
#TAVR #Amyloidosis
@JoaoCavalcante @Marco_Merlo
Thomas Treibel @ThomasTreibel Jun 2, 2025
2/3_👥 N=226 (mean age 85)
🔹 71% had AVR (mostly TAVI)
🔹 32% received tafamidis
🔍 Results:
Both AVR and tafamidis independently ↓ mortality
Dual therapy (AVR + tafamidis) = best outcomes
Survival similar to patients with lone AS undergoing AVR
#EHJ #ValveDisease @MdNitsche
View quoted post on X
Thomas Treibel @ThomasTreibel
2/3_👥 N=226 (mean age 85)
🔹 71% had AVR (mostly TAVI)
🔹 32% received tafamidis
🔍 Results:
Both AVR and tafamidis independently ↓ mortality
Dual therapy (AVR + tafamidis) = best outcomes
Survival similar to patients with lone AS undergoing AVR
#EHJ #ValveDisease @MdNitsche
Thomas Treibel @ThomasTreibel Jun 2, 2025
1/3_📢 Excited to see the results of our transatlantic registry published in #EHJ.
Patients with both aortic stenosis (AS) and transthyretin cardiac amyloidosis (ATTR-CA)—a group with unclear optimal management. Can AVR and tafamidis improve survival?
📄doi.org/10.1093/eurhea…
View quoted post on X